1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections

BACKGROUND: Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits bacterial replication and has in vitro activity against key pathogens, including drug-resistant strains, associated with a range of infections. METHODS: This phase IIa single-center...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Open Forum Infect Dis
Главные авторы: Scangarella-Oman, Nicole, Hossain, Mohammad, Tiemeyer Jr., Timothy, Perry, Caroline R, Tiffany, Courtney, Raychaudhuri, Aparna, Dumont, Etienne
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1346
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы